SCHEMBL6070951

SCHEMBL6070951

O=[N+]([O-])c1ccc2[nH]c3c(c2c1)CCc1c[nH]nc1-3

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
TDP1 Q9NUW8 2/20 0.55
LMNA P02545 2/20 0.55
HTT P42858 1/20 0.55
NCOA1 Q15788 1/20 0.55
NCOA3 Q9Y6Q9 1/20 0.55
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
GFER P55789 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
GSK3B P49841 8/20 0.48
POLB P06746 1/20 0.46
CA12 O43570 1/20 0.45
CA9 Q16790 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CCNB2 O95067 7/20 0.44
CDK1 P06493 7/20 0.44
CCNB1 P14635 7/20 0.44
CDK5 Q00535 7/20 0.44
CDK5R1 Q15078 7/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071081 0.91 MAPT (0.44) MAPTTDP1LMNAHTTNCOA1
SCHEMBL6070722 0.79 MAPK10 (0.59) MAPTLMNAMEN1KMT2AGFER
SCHEMBL6071270 0.79 PRKD1 (0.47) MAPTTDP1LMNAMEN1KMT2A
SCHEMBL6070734 0.77 GSK3B (0.47) MAPTTDP1KMT2ASMN1; SMN2GSK3B
SCHEMBL6070686 0.77 MAPK10 (0.62) MAPTTDP1LMNAHTTMEN1
SCHEMBL6070835 0.77 MPL (0.50) MAPTLMNAMEN1KMT2AGFER
SCHEMBL6071604 0.76 MAPK10 (0.61) MAPTLMNAMEN1KMT2AGFER
SCHEMBL6070582 0.75 MAPK10 (0.45) MAPTTDP1LMNAMEN1KMT2A
SCHEMBL6070802 0.74 MEN1 (0.49) MAPTMEN1KMT2ASMN1; SMN2GSK3B
SCHEMBL6071266 0.72 KDM4E (0.62) MAPTLMNAHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 MAPT 639/4885TDP1 712/4885LMNA 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.